Dr. Conn moved to Vanderbilt University in 2003 where he is the founding director of the VCNDD, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. By 2011 the VCNDD had grown to approximately 100 full time scientists and under his leadership raised over $100M in external research funding. In addition, the VCNDD advanced novel molecules from multiple major programs into development for major brain disorders with industry partners, including Johnson and Johnson, Astrazeneca, Bristol Myers Squibb, and others. Each of these major efforts are focused on novel mechanisms for therapeutic action that have come from the basic research efforts of Dr. Conn and his collaborators. Dr. Conn has served as Associate Editor and Editor in Chief of Molecular Pharmacology and in editorial positions with multiple other international journals. He has served the Scientific Advisory Boards of multiple foundations, research institutes, and companies. He served as Chairman of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET), Fellow of the American Association for the Advancement of Science, and on multiple national and international committees. He has received numerous awards, including the NARSAD Essel Distinguished Investigator Award, the ASPET-Astellas Award in Translational Pharmacology, the Pharmacia - ASPET Award for Experimental Therapeutics, the Charles R. Park Award for Basic Research Revealing Insights into Physiology and Pathophysiology, the PhRMA Foundation Award for Excellence in Pharmacology and Toxicology. V. Sagar Sethi Mental Health Research Award, Jacob K. Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders & Stroke. He was named as an ISI Most- Cited Scientists in Pharmacology & Toxicology and the Lee University 2008 Distinguished Alumnus of the Year. Dr. Conn’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other serious brain disorders.